ANAVEX®2-73 Demonstrates Promising Results in Parkinson’s Disease Phase 2 Extension Study
Anavex Life Sciences has announced positive results from its 48-week Phase 2 extension study of ANAVEX®2-73 (blarcamesine) in patients with Parkinson’s disease dementia. This clinical-stage […]